文献速递肺外科

非小细胞原位癌行亚肺叶切除与肺叶切除的结局比较

Outcomes after sublobar resection versus lobectomy in non-small cell carcinoma in situ.
PubMed 文献 · J Thorac Cardiovasc Surg · 2022-06-01

基于美国国家癌症数据库2004至2017年临床Tis N0 M0、肿瘤≤2 cm的非小细胞肺癌患者707例,比较亚肺叶切除与肺叶切除的生存结局。亚肺叶切除组401例(56.7%),肺叶切除组306例(43.3%),两组5年总生存率分别为85.1%和88.9%(P=0.341),多变量分析无差异(风险比1.044,P=0.885)。亚肺叶切除组中50.9%行淋巴结采样,采样与未采样总生存率分别为84.9%和85.0%(P=0.741)。

要点

  • 临床Tis N0 M0、肿瘤≤2 cm非小细胞肺癌中,亚肺叶切除与肺叶切除的总生存无差异。
  • 亚肺叶切除组5年总生存率85.1%,肺叶切除组88.9%(P=0.341)。
  • 亚肺叶切除组中淋巴结采样与未采样总生存率分别为84.9%和85.0%(P=0.741)。

核心结论

  • 在临床Tis N0 M0、肿瘤≤2 cm的非小细胞肺癌患者中,亚肺叶切除与肺叶切除的总生存无差异。
  • 亚肺叶切除可能是该人群合适的手术选择。
  • 在接受亚肺叶切除的患者中,淋巴结采样与总生存改善无关。

研究设计与样本

  • 使用美国国家癌症数据库识别2004至2017年诊断为非小细胞肺癌临床Tis N0 M0且肿瘤大小≤2 cm的患者。
  • 共纳入707例患者,其中亚肺叶切除401例(56.7%),肺叶切除306例(43.3%)。
  • 采用χ2检验比较不同手术类型的亚组差异,采用Kaplan-Meier法和Cox比例风险模型比较总生存。

主要发现

  • 亚肺叶切除组5年总生存率为85.1%,肺叶切除组为88.9%(P=0.341),两组无差异。
  • 多变量生存分析显示治疗组间总生存无差异(风险比1.044,P=0.885)。
  • 亚肺叶切除组中50.9%的患者接受了淋巴结采样。
  • 在亚肺叶切除组中,淋巴结采样与未采样者的总生存率分别为84.9%和85.0%(P=0.741),淋巴结采样与生存改善无关。

关键数值与推荐

  • 指南将肿瘤≤2 cm且纯原位癌组织学的非小细胞肺癌患者确定为亚肺叶切除的候选者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Guidelines for treatment of non-small cell lung cancer identify patients with tumors ≤2 cm and pure carcinoma in situ histology as candidates for sublobar resection. Although the merits of lobectomy, sublobar resection, and lymphoid (LN) sampling, have been investigated in early-stage non-small cell lung cancer, evaluation of these modalities in patients with IS disease can provide meaningful clinical information. This study aims to compare these operations and their relationship with regional LN sampling in this population. METHODS: The National Cancer Database was used to identify patients diagnosed with non-small cell lung cancer clinical Tis N0 M0 with a tumor size ≤2 cm from 2004 to 2017. The χ2 tests were used to examine subgroup differences by type of surgery. Kaplan-Meier method and Cox proportional hazard model were used to compare overall survival. RESULTS: Of 707 patients, 56.7% (401 out of 707) underwent sublobar resection and 43.3% (306 out of 707) underwent lobectomy. There was no difference in 5-year overall survival in the sublobar resection group (85.1%) compared with the lobectomy group (88.9%; P = .341). Multivariable survival analyses showed no difference in overall survival (hazard ratio, 1.044; P = .885) in the treatment groups. LN sampling was performed in 50.9% of patients treated with sublobar resection. In this group, LN sampling was not associated with improved survival (84.9% vs 85.0%; P = .741). CONCLUSIONS: We observed no difference in overall survival between sublobar resection and lobectomy in patients with cTis N0 M0 non-small cell lung cancer with tumors ≤2 cm. Sublobar resection may be an appropriate surgical option for this population. LN sampling was not associated with improved survival in patients treated with sublobar resection.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Perez Holguin RA, Olecki EJ, Wong WG, et al. Outcomes after sublobar resection versus lobectomy in non-small cell carcinoma in situ. J Thorac Cardiovasc Surg. 2022. PMID: 35760619. doi:10.1016/j.jtcvs.2022.05.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。